• 中文简体
  • 中文繁体
  • English
  • ABOUT IASO
    OverviewManagement TeamScientific Advisory BoardPartnership
  • SCIENCE & PRODUCTS
    PipelineTechnology PlatformsManufacturingPublictaionsExpanded Access
  • NEWS
    Press ReleaseMedia Report
  • CAREERS
    Growth & DevelopmentWorking at IASOOpportunities
  • CONTACT

We always innovate to
deliver cures
to global patients

We are focused on development of 

novel cell therapies for oncology and 

autoimmune diseases

Well-established end-to-end R&D platform and proprietary manufacturing site

  • Pipeline

    We are committed to developing cell therapies and antibody drugs. we now have a diverse pipeline

  • Technology platform

    We have a well-established end-to-end R&D platform and proprietary manufacturing site

  • Manufacturing

    Our mature and stable CMC platform technology enables large-scale, high-quality manufacturing

News

20/052025

IASO Bio Celebrates Grand Opening of Shanghai Waigaoqiao Global R&D Center and Successfully Hosts Forum on China's Cell Therapy Globalization

09/052025

IASO Bio Receives Orphan Drug Designation from the Saudi Food and Drug Authority for Equecabtagene Autoleucel

28/032025

IASO Bio Announces Approval of New Drug Application for Equecabtagene Autoleucel by the Macau Pharmaceutical Administration Bureau

More
  • ABOUT IASO
  • SCIENCE & PRODUCTS
  • NEWS
  • CAREERS
  • CONTACT
Copyright © 2023 南京驯鹿生物技术股份有限公司
苏ICP备2021047135号
Privacy Policy | Terms of Use

WeChat
LinkedIn
i-connection